Patient preferences in the treatment of diabetic retinopathy

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 229-237

  Wirostko, Barbara ^a   Beusterien, Kathleen ^b   Grinspan, Jessica ^b   Ciulla, Thomas ^c   Gonder, John ^d   Barsdorf, Alexandra ^a   Pleil, Andreas ^a  

^a PFIZER INC   (United States)

^b ICON PLC   (United Kingdom)

^c MIDWEST EYE INSTITUTE   (United States)

^d Ivey Eye Institute   (Canada)

Author keywords

Conjoint analysis; Diabetes; Ophthalmology; Patient preference; Retinopathy

Indexed keywords

VASCULOTROPIN INHIBITOR;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DIABETIC RETINOPATHY; FEMALE; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT CARE; PATIENT PREFERENCE; RETINA MACULA EDEMA; STEROID THERAPY; VISUAL ACUITY;

EID: 84866478976     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S11972     Document Type: Article

References (37)

1. Brown AB, Meltzer DO, Chin MH, Huang ES. Perceptions of quality-of-life effects of treatments for diabetes mellitus in vulnerable and nonvulnerable older patients. J Am Geriatr Soc. 2008;56: 1183-1190.
2. Sloan FA, Padròn NA, Platt AC. Preferences, beliefs, and self-management of diabetes. Health Serv Res. 2009;44:1068-1087.
3. McGlynn E, Asch S, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635-2645.
4. Anderson RT, Skovlund SE, Marrero D, et al. Development and validation of the Insulin Treatment Satisfaction Questionnaire. Clin Ther. 2004;26:565-578.
5. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P. Insulin-based versus triple oral therapy for newly diagnosed Type 2 diabetes: Which is better? Diabetes Care. 2009;32:1789-1795.
6. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007;16:1251-1265.
7. Huang ES, Shook M, Jin L, Chin MH, Meltzer DO. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care. 2006;29: 259-264.
8. Hutchinson A, McIntosh A, Peters J, et al. Clinical Guidelines and Evidence Review for Type 2 Diabetes. Diabetic retinopathy: Early management and screening. Sheffield, UK: ScHARR, University of Sheffield; 2001.
9. Lee J, Bailey G. Diabetic retinopathy. Access Media Group LLC, c2000-10 [Updated 2007 June]. Available from: http://www. allaboutvision.com/conditions/diabetic.htm. Accessed 2008 Sep 16.
10. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic-study of diabetic retinopathy: The long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
11. Saaddine JB, Honeycutt AA, Narayan KM, et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol. 2008;126: 1740-1747.
12. Sammartin C, Gilmore J. Statistics Canada. Diabetes care in Canada: Results from selected provinces and territory, 2005. [Updated 2006 Oct 20] Available from: http://www.statcan.gc.ca/pub/82-621-x/2006002/4053724-eng. htm#source. Accessed 2008 Sep 16.
13. Early Treatment Diabetic Retinopathy Study (ETDRS) research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103: 1796-1806.
14. Ferris FL III. How effective are treatments for diabetic retinopathy? JAMA. 1993;269:1290-1291.
15. Han Y, Schneck ME, Bearse MA, et al. Formulation and evaluation of a predictive model to identify the sites of future diabetic retinopathy. Invest Ophthalmol Vis Sci. 2004;45:4106-4112.
16. Churchill AJ, Carter JG, Ramsden C, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:3611-3616.
17. Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol. 1976;81:383-396.
18. Chalam KV, Lin S, Mostafa S. Management of diabetic retinopathy in the twenty-first century. Northeast Florida Medicine. 2005;569(2): 8-15.
19. Dowler J. Laser management of diabetic retinopathy. Journal of the Royal Society of Medicine. 2003;96:277-279. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artidh539507. Accessed 2010 Aug 28.
20. Early Treatment of Diabetic Retinopathy Study Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766-785.
21. Wirostko B, Wong T, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res. 2008;27:608-621.
22. Brunner S, Schernthaner G, Satler M, et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy-first in vivo data. Invest Ophthalmol Vis Sci. 2009;50:392-398.
23. Green PE, Srinivasan V. Conjoint analysis in marketing: New developments with implications for research and practice. Journal of Marketing. 1990;54:3-517.
24. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320:1530-1533.
25. Beusterien KM, Dziekan K, Flood E, et al. Understanding patient preferences for HIV medications using adaptive conjoint analysis: Feasibility assessment. Value Health. 2005;8:453-461.
26. Bhargava JS, Patel B, Foss AJ, et al. Views of glaucoma patients on aspects of their treatment: An assessment of patient preference by conjoint analysis. Invest Ophthalmol Vis Sci. 2006;47:2885-2888.
27. Blankenship GW. Diabetic macular edema and Argon laser photocoagulation: A prospective randomized study. Ophthalmology. 1979;86: 69-75.
28. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: A literature review. Retina. 2007;27:816-824.
29. Margolis R, Singh R, Bhatnagar P, Kaiser P. Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmol Scand. 2008;1:105-110.
30. Sutter F, Simpson J, Gillies M. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebocontrolled clinical trial. Ophthalmology. 2004;111:2044-2049.
31. Mohamed Q, Gillies M, Wong T. Management of diabetic retinopathy: A systematic review. JAMA. 2007;298:902-916.
32. Seiberth V, Alexandridis E. Function of the diabetic retina after panretinal argon laser photocoagulation. Influence of the intensity of the coagulation spots. Ophthalmologica. 1991;202:10-17.
33. Seiberth V, Schatanek S, Alexandridis E. Panretinal photocoagulation in diabetic retinopathy: Argon versus dye laser coagulation. Graefes Arch Clin Exp Ophthalmol. 1993,231:318-322.
34. Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis. 2004; 63:1372-1378.
35. ACA Technical Paper. Sawtooth Software, Sequim, WA. Available from: http://www.sawtoothsoftware.com. Accessed 2008 Nov 13.
36. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009;116:1225. e1.
37. Artunay O, Yuzbasioglu E, Rasier R, Sengül A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intraviteral bevacizumab (Avastin) injection. Eye. 2009;23:2187-2193.